Practical Diabetes is an esteemed journal dedicated to advancing the understanding and management of diabetes and related metabolic disorders. Published by John Wiley & Sons Ltd, this journal serves as a vital resource for healthcare professionals, researchers, and students seeking to explore the latest findings and practical applications in the field of endocrinology. With an ISSN of 2047-2897, it has established itself as a respected outlet for impactful research since its inception in 2011, with a convergence period extending until 2024. Although currently listed in Q4 for Endocrinology, Diabetes, and Metabolism and Q3 for Internal Medicine, the journal is committed to improving its rank and increasing its relevance in a competitive academic landscape. While not an open-access publication, Practical Diabetes provides valuable insights and evidence-based practices that are crucial for improving patient outcomes. Researchers and practitioners alike will find a wealth of knowledge to inform their work and enhance their understanding of diabetes management, making this journal an essential addition to any academic library collection.

Diabetology & Metabolic Syndrome is a premier open-access journal published by BMC, dedicated to advancing the field of endocrinology, diabetes, and metabolic syndrome. Since its inception in 2009, the journal has established itself as a leading platform for original research, reviews, and clinical studies, offering comprehensive insights into the complexities of metabolic diseases. With an impressive ranking in the 2023 category quartiles as Q1 in both Endocrinology, Diabetes and Metabolism, and Internal Medicine, it stands among the top-tier journals in its field. Researchers will appreciate its strong emphasis on disseminating critical findings that influence clinical practices and public health policies. Accessible to a global audience, Diabetology & Metabolic Syndrome's commitment to open access enables the distribution of high-quality research without barriers, fostering an inclusive environment for knowledge sharing. With a strategic focus on the intersection of diabetes management and metabolic disorders, this journal is essential for professionals seeking to stay abreast of the latest developments and contribute to a vital area of healthcare.

Diabetes Technology & Therapeutics is a leading journal published by MARY ANN LIEBERT, INC, dedicated to advancing the field of diabetes management through innovative technologies and therapeutic strategies. With an impressive impact factor and recognized as a Q1 journal in Endocrinology, Diabetes and Metabolism, as well as Medical Laboratory Technology, it occupies a pivotal position in the academic landscape. This esteemed publication features a comprehensive range of articles that cover cutting-edge research, clinical applications, and developments in diabetes care from 1999 to 2024, making it a critical resource for researchers, health professionals, and students alike. The journal is committed to fostering dialogue between disciplines, especially given its strong rankings in various scientific categories including the 98th percentile in Medical Laboratory Technology. By opting for subscription-based access, readers gain insight into the latest innovations that are shaping diabetes technology and treatment paradigms, thereby enhancing patient outcomes and advancing the scientific community's understanding of this complex disease.

DIABETES OBESITY & METABOLISM, published by Wiley, is a premier international journal dedicated to the fields of endocrinology, diabetes, and metabolic disorders. With an impressive impact factor and its status as a Q1 journal in multiple categories—including Endocrinology and Internal Medicine—this publication is highly regarded in the academic community. Since its inception in 1999, the journal has served as a crucial platform for the dissemination of cutting-edge research, reviews, and clinical studies, driving advancements in understanding and treatment of diabetes and obesity. Researchers and professionals alike benefit from its rigorous peer-review process and extensive reach, as it aims to bridge the gap between laboratory findings and clinical applications. Although not an Open Access journal, articles are accessible through institutional subscriptions, ensuring that vital knowledge reaches those committed to enhancing patient care and expanding the scientific body of work in these pivotal areas.

Diabetes Therapy is a prominent open access journal published by SPRINGER HEIDELBERG, dedicated to advancing our understanding of diabetes management and therapeutic strategies. Since its inception in 2010, the journal has provided a platform for high-quality research, showcasing innovative studies and clinical advances aimed at improving care for individuals with diabetes. With an established impact factor and categorized within the Q2 quartile in both Endocrinology, Diabetes and Metabolism and Internal Medicine in 2023, it ranks among the top journals in its field, reflecting its significant contribution to medical knowledge. Researchers, healthcare professionals, and students benefit from its comprehensive coverage of critical topics, ranging from pharmacological advancements to lifestyle interventions and cutting-edge technologies in diabetes management. With a Scopus rank placing it 35th in Internal Medicine, and 68th in Endocrinology, Diabetes, and Metabolism, Diabetes Therapy is recognized for its robust peer-reviewed content, making it an essential resource for anyone engaged in diabetes research and care.

Diabetes Mellitus, published by the Endocrinology Research Centre in the Russian Federation, is an esteemed open-access journal dedicated to the field of endocrinology, diabetes, and metabolism. Since its inception in 1998, this journal has been a pivotal platform for disseminating cutting-edge research and comprehensive reviews that address the multifaceted challenges posed by diabetes. With its current quartile ranking of Q4 in Endocrinology and the associated fields, as well as commendable involvement in the broader scope of Internal Medicine, Diabetes Mellitus plays a crucial role in enhancing clinical practices and informing innovative therapeutic strategies. The journal caters to a diverse audience of researchers, healthcare professionals, and students, particularly those seeking to expand their knowledge and improve patient outcomes in diabetes care. With a commitment to fostering scientific conversation and collaboration, Diabetes Mellitus is an invaluable resource for anyone engaged in the fight against diabetes and its complications.

DIABETES & METABOLISM, published by MASSON EDITEUR in France, is a leading academic journal dedicated to the fields of endocrinology, diabetes, and metabolism. With an impressive Impact Factor reflecting its esteemed reputation, the journal has been ranked in the Q1 category across multiple disciplines including Endocrinology, Internal Medicine, and more, showcasing its significance and influence in the scientific community. Since its inception in 1996 and continuing its contributions through 2024, DIABETES & METABOLISM systematically disseminates high-quality research findings, reviews, and clinical studies aimed at furthering knowledge and encouraging innovation in metabolic diseases. Although not an open-access journal, it ensures that valuable research is accessible to a broad audience through institutional subscriptions and affiliations. As a key resource for researchers, clinicians, and students alike, this journal stands at the forefront of advancing understanding and treatment options in diabetes and related metabolic disorders, making it an essential addition to any academic library.

Journal of Diabetes Investigation is a prestigious open-access journal published by WILEY, dedicated to advancing knowledge in the fields of Endocrinology, Diabetes, and Metabolism. With its ISSN 2040-1116 and E-ISSN 2040-1124, the journal provides a vital platform for researchers, healthcare professionals, and students to disseminate high-quality research, foster innovative ideas, and engage with cutting-edge developments in diabetes investigation. Since its inception in 2010, the journal has established a solid reputation, ranking in Q2 for Endocrinology and Diabetes and Metabolism, and Q1 for both Internal Medicine and Miscellaneous Medicine categories in 2023. Its Scopus rankings further underscore its impact, notably at the 76th percentile in Internal Medicine. The open access model, adopted in 2014, ensures that vital information is freely available, promoting global collaboration and knowledge sharing. The journal is not only a reflection of Australia's commitment to medical research but also a beacon for advancements that can ultimately enhance patient outcomes in diabetes care.

DIABETES RESEARCH AND CLINICAL PRACTICE, published by Elsevier Ireland Ltd, is a leading peer-reviewed journal in the realms of endocrinology, diabetes, and internal medicine. With a prestigious Q1 classification across several categories, including Endocrinology, Diabetes and Metabolism, and Internal Medicine, this journal is recognized for its impactful contributions to advancing knowledge and clinical practice in diabetes care, boasting an impressive impact factor that underscores its significance in the academic community. Spanning from 1985 to 2024, this journal not only disseminates high-quality research but also serves as a critical resource for healthcare professionals, researchers, and students alike who are focused on addressing the global diabetes epidemic. With its comprehensive scope and commitment to fostering innovative findings, DIABETES RESEARCH AND CLINICAL PRACTICE remains at the forefront of its field, fostering collaboration and discovery to improve patient outcomes.

JOURNAL OF DIABETES AND ITS COMPLICATIONS is a distinguished peer-reviewed journal published by Elsevier Science Inc, dedicated to advancing the knowledge and management of diabetes and its multifaceted complications. With an ISSN of 1056-8727 and E-ISSN 1873-460X, this journal has established its significance in the fields of Endocrinology, Diabetes and Metabolism, and Internal Medicine, as reflected in its Q2 and Q1 quartile rankings for 2023, and its commendable Scopus rankings. The journal, which has been converging knowledge since 1992 and continues to publish vital research until 2024, serves as a platform for researchers, professionals, and students aiming to delve deeper into the mechanisms, treatment, and implications of diabetes and its related disorders. While access is not open, the journal remains a critical resource for those invested in understanding and combating the challenges posed by diabetes, ultimately contributing to better health outcomes.